EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Troxerutin is a novel osmotic agent for peritoneal dialysis with protective cardiovascular actions

Valeria Kopytina iD, Vanessa Marchant iD, Raquel Rodrigues-Diez iD, Lucía Pascual-Antón iD, Nora Toggweiler, Lisa Strahl, Jamie Kane iD, Antonio Tejera-Muñoz iD, Marcelino Cortés iD, David Sucunza iD, Juan J Vaquero iD, Marc Vervloet iD und 5 weitere

Nephrology Dialysis Transplantation · 2025

DOI: 10.1093/ndt/gfaf249 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, 2025. Verfasst von Valeria Kopytina und 16 weiteren Autor:innen. Beteiligte Einrichtung: Tissue and Organ Homeostasis Program, Cell-Cell Communication and Inflammation Unit, Centro de Biología Molecular Severo Ochoa, Consejo Superior de I…. Hauptthemen laut MEDLINE: Peritoneal Dialysis, Hydroxyethylrutoside, Dialysis Solutions, Cardiovascular Diseases. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European Union, Spanish Ministry of Science and Innovation, Fondo Europeo de Desarrollo Regional.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and hypothesis End-stage renal disease patients require peritoneal dialysis (PD) as a life-saving therapy; however, they continue to experience systemic inflammation and increased cardiovascular pathology. These complications can be exacerbated by exposure to PD solutions (PDS) containing glucose. This highlights the clinical unmet need for novel osmotic agents to replace glucose. Here, we tested troxerutin, a Food and Drug Administration–approved drug, as a potential osmotic agent.

Methods

To evaluate troxerutin osmotic and non-toxic effects, in vitro and in vivo experiments were carried out using artificial membranes, mice and cultured human mesothelial cells (MCs). The local and systemic consequences of chronic peritoneal exposure to PDS associated to renal insufficiency were investigated in a preclinical model. 5/6 nephrectomized C57BL/6J mice were daily exposed to glucose- or troxerutin-PDS for 60 days, then evaluating tissue damage, proinflammatory markers and cardiac damage.

Results

In vitro and in vivo studies revealed that troxerutin exhibits similar osmotic and ultrafiltration capacities to glucose, but with colloidal properties. Moreover, only glucose, but not troxerutin, reduced MC viability, induced mesothelial-to-mesenchymal transition, and increased damage markers (such as interleukin-6 and vascular endothelial growth factor A). In the preclinical model, long-term treatment with glucose-PDS, but not troxerutin-PDS, significantly increased peritoneal membrane thickening, tissue proinflammatory markers (evaluated in peritoneum, kidney, heart and aorta) and cardiovascular damage (cardiac hypertrophy and fibrosis) in mice. These preclinical data clearly demonstrate the wide deleterious effects of chronic peritoneal exposure to glucose-containing PDS in mice with kidney insufficiency and that the replacement of glucose with troxerutin notably reduces these effects.

Conclusion

Troxerutin emerges as a more biocompatible alternative to glucose as an osmotic agent for PD therapy, exhibiting no adverse local or systemic side effects in preclinical studies. This research presents a novel approach to reduce cardiovascular complications of PD in end-stage kidney disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peritoneal DialysisHydroxyethylrutosideDialysis SolutionsCardiovascular DiseasesKidney Failure, ChronicAnimalsMiceHumansMice, Inbred C57BLMaleCells, CulturedGlucose

Stichwörter der Autor:innen

biocompatibilitycardiovascular diseasekidney replacement therapyosmotic agentperitoneal dialysis

Substanzen

troxerutinHydroxyethylrutosideDialysis SolutionsGlucose

Autor:innen und Institutionen

  • Tissue and Organ Homeostasis Program, Cell-Cell Communication and Inflammation Unit, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas, Madrid, Spain.
  • Spanish Society of Primary Care Physicians (SEMERGEN), Madrid, Spain.
  • Cellular Biology in Renal Diseases Laboratory, Universidad Autónoma de Madrid, IIS-Fundación Jiménez Díaz, Madrid, Spain.
  • RICORS2040, Madrid, Spain.
  • University Center for Health Sciences - HM Hospitals (CUHMED), Camilo José Cela University, Madrid, Spain.
  • Physiology Department, Universidad Complutense de Madrid-CIBERCV, Madrid, Spain.

ORCID-Profile: Valeria Kopytina, Vanessa Marchant, Raquel Rodrigues-Diez, Lucía Pascual-Antón, Jamie Kane, Antonio Tejera-Muñoz, Marcelino Cortés, David Sucunza, Juan J Vaquero, Marc Vervloet, Etto C Eringa, Marta Ruiz-Ortega, Manuel López-Cabrera, Guadalupe T González-Mateo

Förderung

  • European Union
  • Spanish Ministry of Science and Innovation
  • Fondo Europeo de Desarrollo Regional
  • Instituto de Salud Carlos III
  • Dutch Heart Foundation
  • ZonMw

Zitieren

APA

Kopytina, V., Marchant, V., Rodrigues-Diez, R., Pascual-Antón, L., Toggweiler, N., Strahl, L., Kane, J., Tejera-Muñoz, A., Cortés, M., Sucunza, D., Vaquero, J. J., Vervloet, M., Piecha, D., Eringa, E. C., Ruiz-Ortega, M., López-Cabrera, M., & González-Mateo, G. T. (2025). Troxerutin is a novel osmotic agent for peritoneal dialysis with protective cardiovascular actions. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfaf249

Vancouver

Kopytina V, Marchant V, Rodrigues-Diez R, Pascual-Antón L, Toggweiler N, Strahl L, et al. Troxerutin is a novel osmotic agent for peritoneal dialysis with protective cardiovascular actions. Nephrology Dialysis Transplantation. 2025. doi:10.1093/ndt/gfaf249

BibTeX
@article{Kopytina2025,
  author = {Kopytina, Valeria and Marchant, Vanessa and Rodrigues-Diez, Raquel and Pascual-Antón, Lucía and Toggweiler, Nora and Strahl, Lisa and Kane, Jamie and Tejera-Muñoz, Antonio and Cortés, Marcelino and Sucunza, David and Vaquero, Juan J and Vervloet, Marc and Piecha, Dorothea and Eringa, Etto C and Ruiz-Ortega, Marta and López-Cabrera, Manuel and González-Mateo, Guadalupe T},
  title = {Troxerutin is a novel osmotic agent for peritoneal dialysis with protective cardiovascular actions},
  journal = {Nephrology Dialysis Transplantation},
  year = {2025},
  doi = {10.1093/ndt/gfaf249}
}
Kostenlos starten →